We found that DIM, or the formulated BR-DIM treatment, could restrict its nuclear localization and inactivate NF-κB DNA-binding activity in prostate [14], breast [15], and pancreatic cancer cells [36], resulting in the inhibition of transcriptional downregulation of several NF-κB downstream genes causing inhibition of cell growth and inducing apoptotic cell death. The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.